shot-button
Maharashtra Elections 2024 Maharashtra Elections 2024
Home > News > India News > Article > Covaxin booster dose trial results likely to come by November say sources

Covaxin booster dose trial results likely to come by November, say sources

Updated on: 30 June,2021 12:00 AM IST  |  New Delhi
ANI |

As many as 12 centres across the country are conducting trials for Covaxin's booster shot.

Covaxin booster dose trial results likely to come by November, say sources

A vial of Covaxin | File Pic

Results of trials of the third booster dose of Bharat Biotech's Covid-19 vaccine Covaxin is expected to come by November this year, sources told ANI.


The booster dose of the indigenously manufactured vaccine was first launched in May, after which the trials began at the All India Institute of Medical Sciences (AIIMS) in Delhi and Patna. As many as 12 centres across the country are conducting trials for Covaxin's booster shot.


The permission to conduct the clinical trials for the third booster dose was granted to Bharat Biotech in April by the Drug Controller General of India (DCGI). The results of the first trial, conducted in May, will come in August.


Meanwhile, for the second trial, final results are expected by November 2021. The trials are aimed at assessing the immunogenicity, safety, reactogenicity and tolerability of the Covaxin booster dose.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK